Remedy Meds to Acquire Thirty Madison, Expanding Telehealth Capabilities Across Men’s, Women’s, and Metabolic Health

Combination pairs leading brands: Remedy Meds, Keeps, Nurx, and Cove, with a nationwide clinician and pharmacy network to expand access to high-demand, digitally scalable treatments.

SUMMIT, N.J., Sept. 3, 2025 /PRNewswire/ — Remedy Meds, LLC, a consumer virtual-care and pharmacy platform, today announced it has entered into a definitive agreement to acquire Thirty Madison, Inc. (“Thirty Madison”). The transaction creates a larger, multi-brand platform across women’s, men’s, and metabolic health.

The transaction, which is valued just north of $500M, will be funded through an all-stock deal. Closing is expected in Q4 2025, subject to customary closing conditions and regulatory review.

Strategic Rationale

  • Scaled, multi-brand platform. Combines Remedy Meds (weight loss), Keeps (men’s hair loss), Nurx (women’s health), and Cove (migraine) under one consumer-centric platform with cross-category trust and funnel efficiency.
  • Integrated care & pharmacy. Nationwide clinician coverage, insurance coverage, and an integrated pharmacy fulfillment network support same-day video visits, rapid prescription review, tailored treatment plans, and direct-to-door delivery.
  • Robust financial performance. Remedy Meds today sits at $450M+ in annual revenue with substantial profitability, allowing Thirty Madison’s profitable, $220M+ revenue business to benefit from the financials of a scaled operating platform.

Executive Quotes

“By bringing together Thirty Madison’s trusted brands with Remedy Med’s acquisition engine, retention system, and pharmacy infrastructure, we will broaden access, shorten time-to-treatment, and maintain the financial discipline that has defined our growth,” said Haris Memon, Founder and CEO of Remedy Meds.

“Thirty Madison and Remedy Meds share a belief that patients deserve a better healthcare experience. Together we will deliver on making high-quality specialty care easier to access for millions of patients across the conditions we serve. I’m grateful to our teammates, clinicians, and partners who made this possible — and incredibly excited for what we’ll build together in this next stage of growth as a part of Remedy Meds,” said Demetri Karagas, CEO and Co-Founder of Thirty Madison.

About Remedy Meds

Remedy Meds is a consumer health platform that combines a performance-driven acquisition engine, a clinical retention system, and a national, integrated pharmacy care network to deliver affordable, convenient treatment for high-demand conditions.

About Thirty Madison

Thirty Madison offers end-to-end, high-quality virtual specialized care for patients experiencing a range of conditions. Through its brands — Keeps for men’s hair loss, Nurx for women’s health, and Cove for migraine — Thirty Madison supports the unique needs of its patients with ongoing access to personalized care and specialty-level telemedicine. Thirty Madison’s unique care model delivers care that is accessible, affordable, and focused on improving outcomes.

Media Contact: media@remedymeds.com

Methuselah Advisors served as financial advisor, and Weil, Gotshal & Manges LLP served as legal counsel to Remedy Meds. Centerview Partners served as financial advisor, and Cooley LLP served as legal counsel to Thirty Madison.

View original content to download multimedia:https://www.prnewswire.com/news-releases/remedy-meds-to-acquire-thirty-madison-expanding-telehealth-capabilities-across-mens-womens-and-metabolic-health-302545572.html

SOURCE Remedy Meds

Staff

Recent Posts

2026 Payer IT Outsourcing Outlook: Outcome-Based Managed Services, Production-Grade GenAI Governance, and Vendor-Risk Enforcement

Black Book Research Q4 flash survey shows health plans shifting from effort-based sourcing to KPI-backed…

9 hours ago

Cosmos Health Is Building a Platform, and Tariffs Are Accelerating the Strategy

CHICAGO, IL / ACCESS Newswire / December 24, 2025 / Healthcare investors have seen this…

12 hours ago

Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$4.1 million upfront with up to approximately $8.3 million of potential additional gross proceeds upon…

12 hours ago

PharmAla Issues Audited Year End 2025 and Unaudited Q1 Fiscal 2026 Financial Statements

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

12 hours ago

MAIA Biotechnology Board Members Continue to Participate in Private Placement Financings

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec.…

12 hours ago